Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017

Executive Summary

Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.


Related Content

Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018
Priority Reviews At US FDA: From Third Quarter Spikes To A Third Quarter Trough
Breakthrough, Priority Review Designations Could Set High-Water Marks In 2018
Breakthrough Therapy Designations Set Quarterly Record
Gene Therapy Guidances Will Focus On Specific Diseases, Gottlieb Says
Priority Review Designations In US: Third Quarter Spike Continues In 2017
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts